medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2013, Number 4

<< Back Next >>

Biotecnol Apl 2013; 30 (4)

Cardiotropic effect of GHRP-6: in vivo characterization by echocardiography

Valiente J, García BD, Guillén G, Santana H, Altruda F, Tarone G, Silengo L, Berlanga J

Language: Spanish
References: 25
Page: 280-284
PDF size: 414.98 Kb.


ABSTRACT

A pharmacological therapy aimed at the multiple targets exposed by the complex pathophysiology of heart failure remains an unmet clinical need. One possible solution is the use of growth hormone secretagogue peptides, which have important cardiotropic properties. The aim of this work was to conduct an experimental evaluation of the effect of growth hormone releasing peptide six (GHRP-6) on heart function. Bi-dimensional experimental echocardiography was used to evaluate the cardiotropic effect of GHRP-6 when 400 µg/kg were administered to Balb/c mice, measuring the ventricular ejection fraction. Dose-dependency was studied with dosages of 100, 200 and 400 µg/kg, and the effect of concomitant beta-blocker usage on the effect of this peptide was assessed in animals chronically treated with metoprolol at 30 mg/kg. GHRP-6 increased the left ventricular ejection fraction without changes on heart rate. This inotropic effect was dose-dependent, and was sustained even in animals chronically treated with metoprolol.


REFERENCES

  1. Ministerio de Salud Pública, Cuba. Anuario estadístico de salud. La Habana: Dirección Nacional de Registros y Estadística de Salud; 2010. Available from: http:// files.sld.cu/dne/files/2011/04/anuario- 2010-e-sin-grafi cos1.pdf

  2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.

  3. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359(5):473-81.

  4. Salazar HP, Talano JV. Viable myocardium: how much is enough? Echocardiography. 2005;22(1):59-70.

  5. Verma A, Meris A, Skali H, Ghali JK, Arnold JM, Bourgoun M, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging. 2008;1(5): 582-91.

  6. Hwang JJ, Dzau VJ, Liew CC. Genomics and the pathophysiology of heart failure. Curr Cardiol Rep. 2001;3(3):198-207.

  7. Mirotsou M, Watanabe CM, Schultz PG, Pratt RE, Dzau VJ. Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. Physiol Genomics. 2003;15(2):115-26.

  8. Pfeffer MA, Braunwald E. Ventricular enlargement following infarction is a modifi able process. Am J Cardiol. 1991; 68(14):127D-31D.

  9. Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail. 2003;5(4):537-44.

  10. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-906.

  11. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575-81.

  12. Benso A, Broglio F, Marafetti L, Lucatello B, Seardo MA, Granata R, et al. Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences. Semin Vasc Med. 2004;4(2):107-14.

  13. Cao JM, Ong H, Chen C. Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends Endocrinol Metab. 2006;17(1):13-8.

  14. Xu XB, Pang JJ, Cao JM, Ni C, Xu RK, Peng XZ, et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol. 2005;289(4):H1643-51.

  15. Berlanga J, Cibrian D, Guevara L, Dominguez H, Alba JS, Seralena A, et al. Growth-hormone-releasing peptide 6 (GHRP-6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond). 2007;112(4):241-50.

  16. Cibrian D, Berlanga J, Guevara L, Valiente J, Guillen GE, Garcia D, et al. Efecto citoprotector cardiaco y extracardiaco del péptido GHRP-6. Biotecnol Apl. 2008;25(3):276-8.

  17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantifi cation. Eur J Echocardiogr. 2006;7(2): 79-108.

  18. Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C. Beta-blocker treatment of dilated cardiomyopathy. Benefi cial effect of carteolol in mice. Circulation. 1991;83(6):2021-8.

  19. Matsuki N, Sakuma Y, Saito H. Pharmacological properties of blood pressure and heart rate control in suncus. Jpn J Pharmacol. 1993;62(1):93-7.

  20. Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and metaanalysis of randomised controlled trials. Intensive Care Med. 2012;38(3):359-67.

  21. Morici N, Sacco A, Oliva F, Ferrari S, Paino R, Milazzo F, et al. Epinephrine for acute decompensated heart failure and low output state: friend or foe? Int J Cardiol. 2011;149(3):384-5.

  22. Torsello A, Bresciani E, Rossoni G, Avallone R, Tulipano G, Cocchi D, et al. Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology. 2003;144(5):1787-92.

  23. Sun Q, Zang WJ, Chen C. Growth hormone secretagogues reduce transient outward K+ current via phospholipase C/protein kinase C signaling pathway in rat ventricular myocytes. Endocrinology. 2010;151(3):1228-35.

  24. Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology. 2000;141(1):60-6.

  25. Isgaard J, Granata R. Ghrelin in cardiovascular disease and atherogenesis. Mol Cell Endocrinol. 2011;340(1):59-64.




2020     |     www.medigraphic.com